



Published in final edited form as:

J Gastroenterol Hepatol. 2006 October ; 21(Suppl 3): S88–S91. doi:10.1111/j.1440-1746.2006.04586.x.

Matrix metalloproteinases, the pros and cons, in liver fibrosis

Yuan-Ping Han

Department of Surgery and Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA

Abstract

Residing in the space of Disse within loose extracellular matrix (ECM) resembling that in basement membranes, the hepatic stellate cells (HSC) remain in quiescence as vitamin A storage cells. In response to liver injury HSC undergo morphologic and functional trans-differentiation, converting from vitamin A-storing, star-like cells into contractile myofibroblastic cells, a process called activation. Accompanying cellular activation, the ECM components in the space of Disse switch from matrices rich in type-IV collagen and laminin, into condensed interstitial ECM, indicating that proteolytic degradation may occur to change the microenvironment in sinusoids as well as the fate of HSC. Indeed, matrix metalloproteinases (MMP), a family of ECM degradative enzymes, are promptly expressed by HSC in response to diverse hepatic toxins. *In vitro* experiments also demonstrated the role of MMP in activation of HSC cultured in 3-D ECM. Conversely, MMP may also contribute to regression of liver fibrosis through cleavage of the fibrillar ECM and promotion of apoptosis among the activated HSC. Thus, MMP play dual roles both bad and good in liver fibrosis, depending on the timing.

Keywords

extracellular matrix; fibrogenesis; hepatic stellate cells; liver fibrosis; matrix metalloproteinase

Matrix metalloproteinases

If cells were seeds then the extracellular matrix (ECM) would be the soil. The mutual interaction between the cells and ECM determines cell fate, tissue specificity, and homeostasis. Controlled and limited proteolytic degradation of the ECM is essential for normal development, and maintenance of tissue homeostasis. Disregulation of matrix metalloproteinase (MMP) is associated with many degenerative diseases.¹ The dynamics of the ECM in tissues are balanced between matrix breakdown, mediated by specific proteinases, and matrix protein synthesis as well as deposition and reorganization processes.² Matrix degradation is carried out by a fine balance between activities of proteinases and their inhibitors. The MMP are a family of zinc metallo-endopeptidases and are responsible for the turnover of the ECM.³ Distinguishing from other proteinases, all MMP have two conserved motifs, namely pro-peptide and catalytic domains.⁴ Located at the N-terminus, the pro-domain of most MMP has approximately 80 amino residues, containing a consensus sequence of PRCXXPD with a critical cysteine. The catalytic domain, approximately 140–200 amino acid residues, holds a zinc ion, which interacts with three conserved histidines in the sequence HEXXHXXGXXHS and a methionine in the motif of TXXXXXXM. Most MMP are secreted into the extracellular milieu while a few are membrane anchored (termed ‘MT-MMP’). Many MMP have a proline-rich hinge region followed by the catalytic domain, and a hemopexin-like C-terminal domain. Substrate specificity is largely determined by the domains located at the C-terminus. For instance, two

gelatinases (MMP-2 and MMP-9) have gelatin-binding domains similar to those found in fibronectin, through which the proteinases can bind denatured type-I collagen or native type-IV collagen.⁵

Many secreted MMP are absent in healthy and resting tissues. In contrast, as a general rule MMP are expressed in active tissues during embryonic development, injury (chemical or mechanical), and disease development as well as cells cultured *in vitro*. In such conditions the cells undergo activation, proliferation, migration and apoptosis. The MMP-mediated breakdown of ECM seems to be indispensable to breach the resting state to permit the cellular functions. Matrix metalloproteinase activities are under extremely restrained control at such multiple levels as transcriptional, translational regulation and auto-inhibition by the pro-domain as well as by the tissue inhibitors of matrix metalloproteinases (TIMP). Furthermore, the proMMP or zymogen is subjected to another hierarchical control, converting of the zymogen through proteolytic cleavage of the pro-domains by upstream activators. Many MMP, during tissue injury and repair, are orchestrated by inflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interleukin-1 (IL-1). A single cytokine may stimulate a certain MMP in one cell type but inhibit the same MMP in another cell type.⁶ Besides cytokines, defined ECM components as well as mechanical stress also determine the expression of MMP.⁷⁻¹¹ In addition to digestion of connective fibrillar and non-fibrillar ECM, MMP can also selectively cleave non-ECM proteins. For instance, MMP-1, -3, and -7, among others, can either directly convert cytokine precursors or release the cytokines, growth factors from ECM or carrier proteins.^{12,13} Many MMP knockout mice are viable, indicating possible redundancy in development, which may, at least in part, be due to the overlapped substrate specificities. In contrast, excessive amounts of MMP are always associated with degenerative diseases such as cancer, arthritis, chronic wounds and liver injury.

MMP play bad roles in liver injury and fibrosis

Liver fibrosis represents chronic wound repair following diverse insults.¹⁴ The ultimate outcome of liver fibrosis is the formation of nodules encapsulated by fibrillar scar matrix.¹⁵ Located within the space of Disse between hepatocytes and sinusoidal endothelial cells, hepatic stellate cells (HSC) play a key role in liver fibrogenesis.¹⁶ In liver fibrogenesis, HSC undergo dramatic morphological and functional changes, a process called 'activation', during which the star-shaped HSC are converted to myofibroblastic cells with increased expression of α -smooth muscle actin and decreased retinoid storage. In fibrogenesis, the normal ECM in the space of Disse rich in basement membrane-like matrices is switched to fibrillar, contractile ECM.¹⁷⁻²⁰ Thus, it is reasonable to speculate that a proteolytic degradation of the normal ECM may occur at the onset of liver fibrogenesis.

Compelling evidence has documented the association of MMP with liver fibrosis. First, MMP are expressed prior to the onset of HSC activation in liver fibrogenesis. For instance, elevation of MMP and their tissue inhibitors occurs quickly after CCl₄-induced liver injury in rats, and the hepatic expression of MMP-3 (stromelysin-1) is detectable as early as 6 h after CCl₄ administration in rats and peaks at 48-72 h.²¹ A comprehensive study was conducted by Ramadori's group, which measured MMP and TIMP expression in liver injury and fibrosis. After a single dose of CCl₄, MMP-13, MMP-2, MMP-9, MT1-MMP, MMP-3 and MMP-10 were all increased, with peak expression coinciding with induction of inflammatory cytokines.²² This indicates the role of MMP in acute wound healing. Additionally, immunostaining of the liver revealed localization of MMP-9, a major MMP in basement membrane-like ECM remodeling. Matrix metalloproteinase-9 was found in the scar areas of active fibrogenesis, indicating that HSC may be an important source of MMP-9 in addition to macrophages.²³ In rat hepatic fibrosis induced by bile duct ligation (BDL), activities of MMP-2 and MMP-9 increased 2 days after ligation, reached maximal levels at day 10, and remained high throughout

the study period, suggesting that sustained tissue damage and inflammation due to chronic cholestasis would induce MMP.²⁴ Expression of MMP is also regarded as an early signal of tissue regeneration. For example, following partial hepatectomy there is rapid induction of urokinase-type plasminogen activator (uPA), as well as MMP-2 and MMP-9.²⁵ The elevations of MMP are detectable as early as 15–30 min after partial hepatectomy, with peak increases by 3–12 h, including the presence of active form of MMP. This indicates that MMP may be involved in mobilization, migration and proliferation of cells during repair and regeneration. In summary, the expression of MMP is an early event in wound healing, involving mobilization of cells through ECM degradation.

Potential role of MMP in HSC activation in liver fibrogenesis

Hepatic stellate cells are the principal cell types to produce ECM in normal liver.^{26,27} Isolated HSC undergo spontaneous activation when plated on plastic. Such *in vitro* activation is also accelerated by addition of Kupffer cell-conditioned medium or soluble factors identified to be pivotal in stimulating HSC; of note, transforming growth factor- β and platelet-derived growth factor are the two most potent mediators.^{28–30} However, most *in vitro* studies have cultured HSC either on plastic or matrix-coated dishes, which do not reflect the ECM environment *in vivo*. Future studies require culture models to mimic the trans-differentiation of HSC in 3-D ECM. In this regard, little is known about the mechanistic link between ECM remodeling and the activation of HSC in 3D ECM. Particularly, it is not clear how MMP participate in the activation of HSC. To investigate this we created a model in which the freshly isolated HSC were embedded in 3-D ECM. This model, as initially described by Imai and Senoo, and Wake *et al.*, reproduces the true quiescent state of the HSC.^{31,32} Using this model, we tested a panel of inflammatory cytokines for their roles in activation of HSC and induction of MMP.³³ To our surprise, 3-D type I collagen produced a marked synergism with IL-1 as a potent cytokine agonist in inducing HSC activation in ECM. Accompanied by the IL-1-induced cellular activation, MMP-9, a type-IV collagenase, is most impressively induced and converted into its active form. Matrix metalloproteinase-13 is also synergistically induced, resulting in the degradation of 3-D matrix. Thus we hypothesized that MMP and their mediated degradation of ECM in the space of Disse were essential for fibrotic activation of HSC in ECM and in liver fibrogenesis (Fig. 1). In line with the clinical observations and experimental model, the fully activated HSC placed in the culture system, lost their ability to produce MMP and to degrade type-I collagen. This hypothesis is currently under scrutiny in animal models with knockout MMP. The decision of when and which MMP are produced by HSC may be vital to the cellular plasticity of quiescent state versus fibrogenesis. At the early stage of the HSC activation, MMP-3, interstitial collagenase (MMP-13) but not TIMP are detected.³⁴ With prolonged culture, interstitial collagenases are downregulated while expression of TIMP is increased, resulting in the net inhibition of degradation and favoring the deposition of ECM. These findings are important because they mirror the pattern of changes in MMP and TIMP expression profile in liver fibrosis.

Matrix metalloproteinases as ‘good guys’ in resolving liver fibrosis

Scarring is controlled in two ways: the deposition and the removal of ECM. There may now be hope for the reversal of cirrhosis, previously regarded as the end-point of liver disease, largely based on the evidence from clinical and animal studies showing that withdrawal of the sources of injury (viral or chemical) can lead to the disappearance of fibrotic tissues.³⁵ For instance, adenoviral-mediated delivery of MMP-1 promotes resolution of fibrotic tissues.³⁶ Conversely, mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl₄-induced liver fibrosis.³⁷ The MMP-mediated resolution of tissue fibrosis may act through ECM degradation as well as by induction of HSC apoptosis. Inhibition of apoptosis of activated HSC by tissue inhibitor of metalloproteinase-1 is mediated

via effects on MMP activity: implications for reversibility of liver fibrosis.³⁸ Despite these preliminary studies, it is totally unknown how the fibrotic tissues are removed *in vivo*. A particularly difficult question is how MMP, which are usually downregulated in established fibrotic tissues, are expressed again during the resolution process. However, it is certainly a dynamic area to address the interaction between the EMC and cells in disease development.

References

1. Parks WC. Matrix metalloproteinases in repair. *Wound Repair Regen* 1999;7:423–32. [PubMed: 10633001]
2. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. *Curr Opin Cell Biol* 1995;7:728–35. [PubMed: 8573349]
3. Werb Z, Chin JR. Extracellular matrix remodeling during morphogenesis. *Ann NY Acad Sci* 1998;857:110–18. [PubMed: 9917836]
4. Nagase H, Woessner JF Jr. The matrix metalloproteinases and their inhibitors. *J Biol Chem* 1999;274(21):491–4.
5. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. *Am J Respir Cell Mol Biol* 1992;7:120–5. [PubMed: 1497900]
6. Han YP, Tuan TL, Hughes M, Wu H, Garner WL. Transforming growth factor-beta- and tumor necrosis factor-alpha- mediated induction and proteolytic activation of MMP-9 in human skin. *J Biol Chem* 2001;276(22):341–50. [PubMed: 11035001]
7. Riikonen T, Westermark J, Koivisto L, Broberg A, Kahari VM, Heino J. Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression. *J Biol Chem* 1995;270(13):548–52.
8. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF- (kappa)B mediated induction of MT1-MMP. *J Cell Sci* 2001;114:131–9. [PubMed: 11112697]
9. Tyagi SC, Kumar SG, Alla SR, Reddy HK, Voelker DJ, Janicki JS. Extracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblast cells. *J Cell Physiol* 1996;167:137–47. [PubMed: 8698831]
10. Yang JH, Briggs WH, Libby P, Lee RT. Small mechanical strains selectively suppress matrix metalloproteinase-1 expression by human vascular smooth muscle cells. *J Biol Chem* 1998;273:6550–5. [PubMed: 9497391]
11. Sun HB, Yokota H. Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading. *Bone* 2001;28:399–403. [PubMed: 11336920]
12. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. *J Clin Invest* 2000;105:143–50. [PubMed: 10642592]
13. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. *Nature* 1994;370:555–7. [PubMed: 8052310]
14. Friedman SL. Cytokines and fibrogenesis. *Semin Liver Dis* 1999;19:129–40. [PubMed: 10422196]
15. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. *Alcohol Clin Exp Res* 1999;23:911–16. [PubMed: 10371413]
16. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis* 2001;21:311–35. [PubMed: 11586463]
17. Benyon RC, Arthur MJ. Matrix degradation and the role of hepatic stellate cells. *Semin Liver Dis* 2001;21:373–84. [PubMed: 11586466]
18. Arenson DM, Friedman SL, Bissell DM. Formation of extracellular matrix in normal rat liver: lipocytes as a major source of proteoglycan. *Gastroenterology* 1988;95:441–7. [PubMed: 3292336]
19. Maher JJ, Bissell DM, Friedman SL, Roll FJ. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. *J Clin Invest* 1988;82:450–9. [PubMed: 3042806]

20. Ramadori G, Rieder H, Knittel T, Dienes HP, Meyer zum Buschenfelde KH. Fat storing cells (FSC) of rat liver synthesize and secrete fibronectin. Comparison with hepatocytes. *J Hepatol* 1987;4:190–7. [PubMed: 3584927]
21. Herbst H, Heinrichs O, Schuppan D, Milani S, Stein H. Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1991;60:295–300. [PubMed: 1685036]
22. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. *Histochem Cell Biol* 2000;113:443–53. [PubMed: 10933221]
23. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. *J Hepatol* 1999;30:48–60. [PubMed: 9927150]
24. Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. *Am J Pathol* 1998;153:1895–902. [PubMed: 9846979]
25. Kim TH, Mars WM, Stolz DB, Petersen BE, Michalopoulos GK. Extracellular matrix remodeling at the early stages of liver regeneration in the rat. *Hepatology* 1997;26:896–904. [PubMed: 9328311]
26. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. *Proc Natl Acad Sci USA* 1985;82:8681–5. [PubMed: 3909149]
27. de Leeuw AM, McCarthy SP, Geerts A, Knook DL. Purified rat liver fat-storing cells in culture divide and contain collagen. *Hepatology* 1984;4:392–403. [PubMed: 6373550]
28. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. *Hepatology* 1990;11:599–605. [PubMed: 2328954]
29. Bachem MG, Meyer D, Melchior R, Sell KM, Gressner AM. Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblast like cells. A potential mechanism of self perpetuation in liver fibrogenesis. *J Clin Invest* 1992;89:19–27. [PubMed: 1729271]
30. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. *J Clin Invest* 1989;84:1780–5. [PubMed: 2556445]
31. Imai K, Senoo H. Morphology of sites of adhesion between hepatic stellate cells (vitamin A-storing cells) and a three-dimensional extracellular matrix. *Anat Rec* 1998;250:430–7. [PubMed: 9566533]
32. Wake K, Motomatsu K, Senoo H. Stellate cells storing retinol in the liver of adult lamprey, *Lampetra japonica*. *Cell Tissue Res* 1987;249:289–99. [PubMed: 3621303]
33. Han YP, Zhou L, Wang J, et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. *J Biol Chem* 2004;279:4820–8. [PubMed: 14617627]
34. Vyas SK, Leyland H, Gentry J, Arthur MJ. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. *Gastroenterology* 1995;109:889–98. [PubMed: 7657119]
35. Benyon RC, Iredale JP. Is liver fibrosis reversible? *Gut* 2000;46:443–6. [PubMed: 10716665]
36. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. *Gastroenterology* 2003;124:445–58. [PubMed: 12557150]
37. Issa R, Zhou X, Trim N, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. *FASEB J* 2003;17:47–9. [PubMed: 12475903]
38. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *J Biol Chem* 2002;277:11069–76. [PubMed: 11796725]

Biography



Han Y-P




Figure 1.

Timeline of events during activation of hepatic stellate cells (HSC) and fibrogenesis in an animal model. In response to injury pro-inflammatory cytokines are promptly increased in wound areas, which induce matrix metalloproteinase (MMP) expression by hepatic cells including HSC. The MMP secreted by HSC degrade the normal extracellular matrix (ECM) in the space of Disse. This cytokine-induced ECM degradation leads to activation of HSC. Consequently, a population of the HSC undergo apoptosis while others trans-differentiate into myofibroblasts that produce fibrillar ECM.